Schwab Charles Investment Management Inc. reduced its position in shares of Xencor Inc (NASDAQ:XNCR) by 12.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 187,461 shares of the biopharmaceutical company’s stock after selling 27,650 shares during the period. Schwab Charles Investment Management Inc. owned 0.40% of Xencor worth $4,297,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of XNCR. FMR LLC raised its stake in Xencor by 77.7% during the 2nd quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after purchasing an additional 2,924,510 shares during the last quarter. State Street Corp raised its stake in Xencor by 11.1% during the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after purchasing an additional 110,474 shares during the last quarter. Artal Group S.A. acquired a new position in shares of Xencor in the 3rd quarter valued at $2,292,000. JPMorgan Chase & Co. raised its stake in shares of Xencor by 48.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 289,500 shares of the biopharmaceutical company’s stock valued at $6,112,000 after buying an additional 93,975 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Xencor by 5.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after buying an additional 90,094 shares in the last quarter. 77.52% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently issued reports on XNCR shares. Piper Jaffray Companies restated a “buy” rating and issued a $35.00 price objective on shares of Xencor in a research note on Sunday, November 12th. Canaccord Genuity set a $36.00 price objective on shares of Xencor and gave the company a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Cantor Fitzgerald began coverage on shares of Xencor in a research note on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 price objective for the company. Finally, ValuEngine cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $30.80.
Shares of Xencor Inc (NASDAQ XNCR) traded down $0.72 during trading hours on Friday, reaching $21.54. 131,690 shares of the company’s stock were exchanged, compared to its average volume of 140,027. Xencor Inc has a 12-month low of $18.55 and a 12-month high of $28.64. The company has a market cap of $1,045.35, a price-to-earnings ratio of -21.54 and a beta of 1.97.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%. analysts predict that Xencor Inc will post -1.1 earnings per share for the current fiscal year.
In other Xencor news, major shareholder John S. Stafford III bought 9,215 shares of Xencor stock in a transaction dated Thursday, December 14th. The shares were bought at an average price of $20.76 per share, with a total value of $191,303.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder John S. Stafford III bought 3,400 shares of Xencor stock in a transaction dated Wednesday, November 8th. The stock was acquired at an average cost of $19.89 per share, for a total transaction of $67,626.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 40,182 shares of company stock worth $811,733. Insiders own 4.03% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Xencor Inc (NASDAQ:XNCR) Position Trimmed by Schwab Charles Investment Management Inc.” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/03/schwab-charles-investment-management-inc-sells-27650-shares-of-xencor-inc-xncr.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.